PD2i algorithm published in Therapeutics and Clinical Risk Management can predict risk of sudden cardiac death

Aug 26 2009

David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that original research conducted using its PD2i algorithm to prospectively predict risk of sudden cardiac death was published in Therapeutics and Clinical Risk Management. Vicor Technologies is a biotechnology company focused on the commercialization of innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i algorithm and software to stratify patients at risk of sudden cardiac death (SCD) and trauma victims in need of life saving intervention.

"Comparison of linear-stochastic and nonlinear-deterministic algorithms in the analysis of 15-minute clinical ECGs to predict risk of arrhythmic death" documents the comparative evaluation of nonlinear algorithms and conventional linear-stochastic measures of heartbeat series in low-to-high risk cardiac patients to prospectively predict risk of arrhythmic (sudden cardiac) death. Vicor's time-dependent, non-linear PD2i algorithm was demonstrated to be the comparatively superior test.

"We are gratified to have this study accepted for publication in Therapeutics and Clinical Risk Management," stated Mr. Fater. "Acceptance in this prestigious, peer-reviewed journal attests to the quality and rigor of the research in which the PD2i is involved. We are also heartened by the results, which attest once again to the PD2i's ability to prospectively predict those at risk of arrhythmic or sudden cardiac death with a high degree of accuracy and consistency," he concluded.

"Comparison of linear-stochastic and nonlinear-deterministic algorithms in the analysis of 15-minute clinical ECGs to predict risk of arrhythmic death" chronicles the study of 397 patients admitted to three emergency room departments for chest pain and determined to be at low-to-high risk of acute myocardial infarction (MI). Fifteen-minute ECGs were recorded and R-R intervals assessed by three non-linear algorithms (PD2i, DFA, ApEn) and four conventional linear-stochastic measures (SDNN, MNN, 1/f-Slope, LF/HF). The sensitivity and relative risk for predicting arrhythmic death was highest at all time-points for the PD2i algorithm.

Therapeutics and Clinical Risk Management, a Dove Press publication, is an international, peer-reviewed journal of clinical therapeutics and risk management focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines. Dove Press specializes in the publication of peer-reviewed journals across the spectrum of science, technology, and medicine using the Open Access publication model.